346 related articles for article (PubMed ID: 33864145)
21. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer and osteoporosis.
Cheung AM; Heisey R; Srighanthan J
Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):532-8. PubMed ID: 24468755
[TBL] [Abstract][Full Text] [Related]
23. Denosumab for cancer-related bone loss.
Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
[TBL] [Abstract][Full Text] [Related]
24. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.
Takahashi S
J Bone Miner Metab; 2023 May; 41(3):307-316. PubMed ID: 37036530
[TBL] [Abstract][Full Text] [Related]
25. Skeletal health in breast cancer survivors.
Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
[TBL] [Abstract][Full Text] [Related]
26. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
[TBL] [Abstract][Full Text] [Related]
27. Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.
Miyashita H; Satoi S; Kuno T; Cruz C; Malamud S; Kim SM
Breast Cancer Res Treat; 2020 Jun; 181(2):279-289. PubMed ID: 32318956
[TBL] [Abstract][Full Text] [Related]
28. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
29. Managing Bone Health in Breast Cancer.
Kearns AE
Endocr Pract; 2023 May; 29(5):408-413. PubMed ID: 36509360
[TBL] [Abstract][Full Text] [Related]
30. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.
Waqas K; Lima Ferreira J; Tsourdi E; Body JJ; Hadji P; Zillikens MC
J Bone Oncol; 2021 Jun; 28():100355. PubMed ID: 33948427
[TBL] [Abstract][Full Text] [Related]
31. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
[TBL] [Abstract][Full Text] [Related]
32. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Takahashi S
Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
[TBL] [Abstract][Full Text] [Related]
33. Bone health in breast cancer.
Pandey P; Sharma A; Gogia A
Curr Probl Cancer; 2023 Jun; 47(3):100959. PubMed ID: 37236055
[TBL] [Abstract][Full Text] [Related]
34. Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.
Body JJ; Bergmann P; Boonen S; Boutsen Y; Devogelaer JP; Goemaere S; Reginster JY; Rozenberg S; Kaufman JM
Osteoporos Int; 2007 Nov; 18(11):1439-50. PubMed ID: 17690930
[TBL] [Abstract][Full Text] [Related]
35. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
36. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia.
Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede H
Clin Endocrinol (Oxf); 2018 Sep; 89(3):280-296. PubMed ID: 29741296
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Logman JFS; Heeg BMS; Botteman MF; Kaura S; van Hout BA
Ann Oncol; 2010 Jul; 21(7):1529-1536. PubMed ID: 19955334
[TBL] [Abstract][Full Text] [Related]
39. Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.
Brufsky AM
Curr Oncol Rep; 2008 Jan; 10(1):18-26. PubMed ID: 18366957
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer therapy and bone.
Stevens Z; Hellig J
Climacteric; 2022 Feb; 25(1):67-72. PubMed ID: 34431442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
